Target intelligence / Profile preview

MicroRNA 1289-2 (miR-1289-2)

Target
miR-1289-2
Molecular classification
MicroRNA, Noncoding RNA, Regulatory RNA, Other (small RNA family)
01

Overview

MicroRNA 1289-2 is a small, noncoding RNA molecule that regulates gene expression by binding to complementary sequences within target mRNAs, resulting in their silencing or degradation. In human cancer biology, particularly oral squamous cell carcinoma, miR-1289-2 exhibits strong tumor suppressor functionality: its expression is reduced in malignant tissue, and restoration via synthetic mimics significantly inhibits tumor cell proliferation both in vitro and in animal models. miR-1289-2 directly targets key genes involved in cell growth and survival, with magnesium transporter 1 (MAGT1) being a principal functional target in OSCC. Early-stage therapeutic research positions miR-1289-2 as a promising molecular target for RNA-based or gene therapy approaches, pending further validation in broader cancer types and clinical studies[1][2].

Other names
hsa-mir-1289-2MIRN1289-2MIR1289-2miR-1289
02

Mechanism of action

Synthetic mimic substituting or restoring endogenous miR-1289 reduces tumor cell growth and represses target gene expression, notably magnesium transporter 1 (MAGT1)

03

Biological functions

Gene expression regulation (post-transcriptional silencing)Tumor suppressionInhibition of cell proliferationPotential role in mRNA transfer into microvesicles
04

Disease associations

Cancer (tumor suppressor role in oral squamous cell carcinoma; possible involvement in other malignancies)Upregulation during H. pylori infection with possible gastric biology effects
05

Safety considerations

No notable safety concerns directly reported for miR-1289-2 mimic therapy in published models (in vivo mouse studies showed no toxic effect during treatment)General concerns with microRNA therapies include off-target gene regulation, immune activation, and delivery system toxicity, but these were not observed for miR-1289-2 in limited animal studies
06

Interacting drugs

No approved drugs directly target miR-1289-2.

1 more in the full profile.

07

Biomarkers

Reduced expression of miR-1289 in OSCC tissues (compared to normal mucosa) can be a biomarker of cancer or disease riskMAGT1 expression (a direct target; upregulated in OSCC, inversely correlated with miR-1289)

Beyond the preview

Go deeper on MicroRNA 1289-2 (miR-1289-2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on MicroRNA 1289-2 (miR-1289-2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call